AKTX Akari Therapeutics Plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1541157 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-86.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-146.3%
ROA-71.8%
ROIC (approx.)-140.0%
Asset turnover—
Leverage & solvency
Liabilities / assets52.2%
Debt / equity0.00x
Current ratio0.48x
Interest coverage-282.65x
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-40.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.11M | $2.08M | $1.46M | $1.09M | $249,000 | $667,000 | $813,000 | $1.25M |
| SG&A expense | $2.57M | $2.52M | $2.17M | $2.14M | $1.98M | $2.45M | $2.71M | $3.05M |
| Operating income | -$4.68M | -$4.60M | -$15.76M | -$3.23M | -$7.40M | -$3.12M | -$3.52M | -$5.28M |
| Interest expense | $85,000 | $80,000 | $61,000 | -$126,000 | $121,000 | $50,000 | $55,000 | $124,000 |
| Pretax income | -$4.84M | -$4.81M | -$15.31M | -$5.21M | -$7.49M | -$1.90M | -$3.71M | -$3.77M |
| Income tax | $0 | $0 | -$859,000 | $85,000 | -$1.09M | $0 | $0 | — |
| Net income | -$4.84M | -$4.81M | -$14.46M | -$5.30M | -$6.40M | -$1.90M | -$3.71M | -$3.77M |
| EBITDA | — | — | — | — | — | — | — | -$5.28M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 265.89B | 143.32B | 118.76B | — | 65.33B | 62.94B | 54.59B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.74M | $7.69M | $2.77M | $5.20M | $2.54M | $2.77M | $2.64M | $2.66M |
| Current assets | $6.28M | $8.32M | $3.59M | $5.46M | $2.95M | $3.30M | $3.35M | $2.95M |
| Goodwill | — | — | — | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M |
| Total assets | $36.58M | $38.62M | $33.89M | $47.89M | $45.38M | $50.91M | $50.96M | $50.56M |
| Current liabilities | $12.98M | $13.94M | $13.41M | $12.35M | $15.57M | $17.14M | $20.91M | $19.91M |
| Total liabilities | $19.08M | $20.03M | $19.51M | $19.56M | $22.69M | $25.31M | $29.21M | $28.33M |
| Shareholders' equity | $17.50M | $18.59M | $14.38M | $28.33M | $22.69M | $25.61M | $21.75M | $22.23M |
| Shares outstanding | 182.81B | 140.03B | 91.57B | 90.54B | 65.23B | 65.23B | 57.75B | 53.19B |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.22M | -$3.11M | -$2.49M | -$3.04M | -$2.12M | -$3.26M | -$2.15M | -$2.12M |
| Financing cash flow | $2.27M | $8.04M | $53,000 | $5.76M | $1.90M | $3.38M | $2.13M | $2.15M |
| Depreciation & amortization | — | — | — | — | — | — | — | $1,000 |
| Stock-based compensation | $537,000 | $711,000 | $305,000 | $471,000 | $685,000 | $719,000 | $1.01M | $1.26M |
Free plan shows the latest 8 periods; Pro shows all 41 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.